Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep238 | Calcium and Bone | ECE2022

Primary hyperparathyroidism and rheumatoid arthritis

Athanassiou Lambros , Kostoglou-Athanassiou Ifigenia , Mavroudi Maria , Tsakiridis Pavlos , Koukosias Nikolaos , Athanassiou Panagiotis

Rheumatoid arthritis is a systemic autoimmune inflammatory disease characterized by severe pain, if left untreated. Primary hyperparathyroidism is a systemic disorder characterized by disordered calcium metabolism leading to increased serum calcium and PTH levels. Primary hyperparathyroidism may be due to the presence of a parathyroid adenoma or parathyroid hyperplasia. The aim was to present a cohort of patients with rheumatoid arthritis who presented with primary hyperparath...

ea0070ep118 | Bone and Calcium | ECE2020

Periodontitis and osteoporosis. A frequent coexistence with dangerous implications

Kostoglou–Athanassiou Ifigenia , Athanassiou Lambros , Spyropoulos Panagiotis , Manta Erasmia , Mavroudi Maria , Giannakopoulos Andreas , Pastroudis Alexandros , Athanassiou Panagiotis

Periodontitis is a serious medical condition which may lead to edentulousness in middle aged patients. It is a chronic inflammatory systemic disorder which affects the oral cavity, the maxilla and mandible. It may be associated with osteoporosis. It presents unique problems in the management of osteoporosis. The patients are in the imminent danger of losing teeth. Some of the antiosteoporotic agents may induce osteonecrosis, while they may complicate the implantation of dental...

ea0070ep130 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Similar effect of tocilizumab, an interleukin-6 receptor antagonist, administered either intravenously or subcutaneously on lipid levels in rheumatoid arthritis

Athanassiou Panagiotis , Athanassiou Lambros , Tzanavari Aikaterini , Gatsiou Marina , Devetzi Eirini , Tsakiridis Pavlos , Mavroudi Maria , Kostoglou-Athanassiou Ifigenia

Tocilizumab is an interleukin-6 receptor antagonist used in the treatment of rheumatoid arthritis (RA). It is known to induce remission and inhibit radiographic progression in RA. Tocilizumab may be administered either intravenously or subcutaneously. Its effect on lipid levels and the cardiovascular risk has not been fully investigated. The aim was to study the effect of tocilizumab administered either iv or sc on disease activity, lipid levels and cardiovascular risk in RA p...

ea0070aep429 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

The management of nonalcoholic fatty liver disease with a choline containing antioxidant compound

Athanassiou Panagiotis , Athanassiou Lambros , Kotrotsios Anastasios , Gatsiou Marina , Tsakiridis Pavlos , Devetzi Eirini , Mavroudi Maria , Kaiafa Georgia , Savopoulos Christos , Kostoglou-Athanassiou Ifigenia

Nonalcoholic fatty liver disease has an increased worldwide prevalence due to obesity and the use of various drugs affecting the liver. The pathogenesis of nonalcoholic fatty liver disease is presently not completely defined. In addition, there is a paucity of agents for its treatment. Choline deficiency has been shown to induce nonalcoholic liver disease. Systemic autoimmune rheumatic diseases require chronic systemic treatment with various agents, which may affect liver func...